argenx’s ALKIVIA Phase 3 Study Demonstrates Rapid and Durable Clinical Improvement with Efgartigimod in Autoimmune Myositis; Johnson & Johnson Reports Phase 2 Nipocalimab Data in Sjögren’s Disease Highlighting Patient-Prioritized Symptom Improvements; Immunocore Unveils Promising Brenetafusp–KIMMTRAK Data in Metastatic Uveal Melanoma; Real-World Study Shows REPATHA Cuts Heart Attack Risk by 20% Compared with Ezetimibe; Health Canada Approves Moderna’s mRNA Flu Vaccine and Combined Influenza-COVID-19 Vaccine
Nov 10, 2026
Get in touch
Please fill in your details to download this article